JPMorgan Chase & Co. started coverage on shares of Twist Bioscience (NASDAQ:TWST) in a research note issued on Sunday. The brokerage set a “neutral” rating and a $25.99 price target on the stock. JPMorgan Chase & Co.’s price objective suggests a potential downside of 1.78% from the company’s previous close.
Other equities analysts also recently issued research reports about the company. Robert W. Baird began coverage on Twist Bioscience in a research report on Monday, November 26th. They set an “outperform” rating for the company. Cowen began coverage on Twist Bioscience in a research report on Monday, November 26th. They set an “outperform” rating for the company.
Twist Bioscience stock traded up $0.96 during mid-day trading on Friday, hitting $26.46. 150,130 shares of the company were exchanged, compared to its average volume of 182,092. Twist Bioscience has a 12-month low of $12.38 and a 12-month high of $29.21.
Twist Bioscience Company Profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Featured Article: What Does Beta Mean In Stock Selection
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.